D-0533-2023 Class II Ongoing
FDA drug recall D-0533-2023 was initiated by Ascend Laboratories, LLC on Mar 14, 2023 and is designated Class II. Reason for recall: CGMP Deviations: Detection of N-nitroso-dabigatran (NDAB) impurity levels above the Acceptable Daily Intake Limit. The recall status is ongoing. Affected quantity: 13,560 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Apr 5, 2023
- Initiation Date
- Mar 14, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 13,560 bottles
Product description
Dabigatran Etexilate Capsules, 75 mg, Rx Only, 60 Capsules per bottle, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-474-60.
Reason for recall
CGMP Deviations: Detection of N-nitroso-dabigatran (NDAB) impurity levels above the Acceptable Daily Intake Limit.
Distribution pattern
Nationwide in the USA.
Code information
Lot #s: 22142462, 22142463, 22142464, Exp 5/2024; 22143000, 22143001, 22143002, Exp 6/2024.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0533-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026